Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults with Variable Disease States: A Meta-analysis of Large Placebo-Controlled Trials

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 2025 Feb 22

PMID 39987306

Authors

Syeda Ayesha Shah

Hasan Mushahid

Ali Salman

Syed Husain Farhan

Fakhar Latif

Rabbia Siddiqi

Abdulqadir J Nashwan

Dmitry Abramov

Abdul Mannan Khan Minhas

Affiliations

Soon will be listed here.

Abstract

Background: Recent guidelines recommend the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors (SGLT2i) in patients suffering from cardiorenal diseases. However, the safety and efficacy of SGLT2i in older adults with atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD) remain unclear.

Methods: Online databases were queried from inception to 11 July 2023 to identify primary or secondary analyses for inclusion. Efficacy outcomes included all-cause mortality, cardiovascular (CV) death, hospitalization for heart failure (HHF), major adverse cardiac events (MACE), CV death/HHF composite, and cardiorenal composite events. Safety endpoints included acute kidney injury (AKI), serious adverse events, genital infections, limb amputation, fractures, urinary tract infections (UTI), and volume depletion. Data were pooled using a random-effects model to derive risk ratios (RRs) and 95% confidence intervals (CIs).

Results: Eight trials with 32,541 older adults identified in primary or secondary analyses were included. In older adults, SGLT2i reduced the risk of all-cause mortality (RR 0.88; 95% CI 0.83- 0.95), CV death (RR 0.82; 95% CI 0.74-0.92), HHF (RR 0.72; 95% CI 0.66-0.79), MACE (RR 0.87; 95% CI 0.77-0.99), CV death/HHF composite (RR 0.78; 95% CI 0.70-0.88), and cardiorenal composite events (RR 0.77; 95% CI 0.70-0.85). For safety endpoints, SGLT2i decreased the risk of serious adverse events (RR 0.92; 95% CI 0.89-0.95) and increased the risk of genital infections (RR 3.48; 95% CI 2.58-4.69).

Conclusions: This analysis of randomized trials demonstrates that SGLT2i are efficacious in older adults. However, since older individuals are often underrepresented in most clinical trials, further research targeting this growing demographic is essential.

References

Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan R, Antunes M . 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39):4043-4140. DOI: 10.1093/eurheartj/ehad192. View

Rossing P, Caramori M, Chan J, Heerspink H, Hurst C, Khunti K . Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int. 2022; 102(5):990-999. DOI: 10.1016/j.kint.2022.06.013. View

Tong D . SGLT2 inhibitors in patients with HFpEF: how old is too old?. J Cardiovasc Aging. 2022; 2. PMC: 9354734. DOI: 10.20517/jca.2022.30. View

Lunati M, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I . SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol Res. 2022; 183:106396. DOI: 10.1016/j.phrs.2022.106396. View

Sinclair A, Bode B, Harris S, Vijapurkar U, Shaw W, Desai M . Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. J Am Geriatr Soc. 2016; 64(3):543-52. PMC: 4819884. DOI: 10.1111/jgs.14028. View

Cahn A, Mosenzon O, Wiviott S, Rozenberg A, Yanuv I, Goodrich E . Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care. 2019; 43(2):468-475. DOI: 10.2337/dc19-1476. View

Monteiro P, Bergenstal R, Toural E, Inzucchi S, Zinman B, Hantel S . Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. Age Ageing. 2019; 48(6):859-866. PMC: 7963112. DOI: 10.1093/ageing/afz096. View

Pratley R, Cannon C, Cherney D, Cosentino F, McGuire D, Noyes Essex M . Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev. 2023; 4(4):e143-e154. DOI: 10.1016/S2666-7568(23)00032-6. View

Martinez F, Serenelli M, Nicolau J, Petrie M, Chiang C, Tereshchenko S . Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation. 2019; 141(2):100-111. DOI: 10.1161/CIRCULATIONAHA.119.044133. View

10.

Yi T, Smyth B, Di Tanna G, Arnott C, Cardoza K, Kang A . Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023; 82(1):84-96.e1. DOI: 10.1053/j.ajkd.2022.12.015. View

11.

Bellary S, Barnett A . SGLT2 inhibitors in older adults: overcoming the age barrier. Lancet Healthy Longev. 2023; 4(4):e127-e128. DOI: 10.1016/S2666-7568(23)00039-9. View

12.

Engler C, Leo M, Pfeifer B, Juchum M, Chen-Koenig D, Poelzl K . Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018. BMJ Open Diabetes Res Care. 2020; 8(1). PMC: 7467522. DOI: 10.1136/bmjdrc-2020-001279. View

13.

Rigato M, Fadini G, Avogaro A . Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023; 25(10):2963-2969. DOI: 10.1111/dom.15193. View

14.

Aldafas R, Crabtree T, Alkharaiji M, Vinogradova Y, Idris I . Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age Ageing. 2024; 53(1). PMC: 10825241. DOI: 10.1093/ageing/afad254. View

15.

Filippatos G, Anker S, Butler J, Farmakis D, Ferreira J, Gollop N . Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced. Eur J Heart Fail. 2022; 24(12):2297-2304. PMC: 10092219. DOI: 10.1002/ejhf.2707. View

16.

Triposkiadis F, Xanthopoulos A, Butler J . Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 74(6):804-813. DOI: 10.1016/j.jacc.2019.06.053. View

17.

Han S, Ha K, Lee N, Kim D . Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study. Diabetes Obes Metab. 2020; 23(3):682-691. PMC: 7898287. DOI: 10.1111/dom.14261. View

18.

Vaduganathan M, Docherty K, Claggett B, Jhund P, de Boer R, Hernandez A . SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022; 400(10354):757-767. DOI: 10.1016/S0140-6736(22)01429-5. View

19.

Usman M, Siddiqi T, Anker S, Bakris G, Bhatt D, Filippatos G . Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. J Am Coll Cardiol. 2023; 81(25):2377-2387. DOI: 10.1016/j.jacc.2023.04.034. View

20.

Neuen B, Young T, Heerspink H, Neal B, Perkovic V, Billot L . SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019; 7(11):845-854. DOI: 10.1016/S2213-8587(19)30256-6. View